Colgate-Palmolive vs Kimberly-Clark: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Colgate-Palmolive Company (CL)

Q3 202631 Jul – 11 Sep 2026

▼2

Colgate beats on earnings but tariffs, weak volumes and index exit weigh

Q2 earnings beat, guidance raised, but tariff costs cloud outlook Colgate beat profit and sales estimates, with margins expanding and full-year earnings guidance raised. But management flagged rising tariff costs and raw materials, and the stock fell 1.8% on the day. The market is weighing solid results against cost pressures ahead.
This is the core earnings event that sets the tone for the period and explains the mixed price reaction.
U.S. volumes flat as shoppers switch to cheaper store brands Colgate's U.S. sales volumes were flat or falling as shoppers trade down to private-label and newer brands. This squeezes growth in its home market and pressures pricing power. It's a broad industry problem, but it directly limits how fast Colgate can grow.
This demand weakness is a key reason the stock struggles despite the earnings beat.
Removed from S&P 100 index, forcing some funds to sell Colgate is being dropped from the S&P 100 index, which means index-tracking funds must sell their shares. That creates mechanical selling pressure around the change date. It doesn't reflect the business itself, but it can push the price down in the short term.
This is a concrete, new event that adds selling pressure on the stock.
Exploring sale of Softsoap, Irish Spring and other personal care brands Colgate is reportedly working with Goldman Sachs to sell some mass-market personal care brands, potentially raising over $1 billion. Selling slower-growing brands could sharpen focus on core oral care, but it also means giving up revenue. The net effect on the stock is unclear.
This is a major strategic move that could reshape the company and is the latest news in the period.

August 202631 Jul – 11 Sep 2026

▼2

Colgate beats on earnings but tariffs, weak volumes and index exit weigh

Q2 earnings beat, guidance raised, but tariff costs cloud outlook Colgate beat profit and sales estimates, with margins expanding and full-year earnings guidance raised. But management flagged rising tariff costs and raw materials, and the stock fell 1.8% on the day. The market is weighing solid results against cost pressures ahead.
This is the core earnings event that sets the tone for the period and explains the mixed price reaction.
U.S. volumes flat as shoppers switch to cheaper store brands Colgate's U.S. sales volumes were flat or falling as shoppers trade down to private-label and newer brands. This squeezes growth in its home market and pressures pricing power. It's a broad industry problem, but it directly limits how fast Colgate can grow.
This demand weakness is a key reason the stock struggles despite the earnings beat.
Removed from S&P 100 index, forcing some funds to sell Colgate is being dropped from the S&P 100 index, which means index-tracking funds must sell their shares. That creates mechanical selling pressure around the change date. It doesn't reflect the business itself, but it can push the price down in the short term.
This is a concrete, new event that adds selling pressure on the stock.
Exploring sale of Softsoap, Irish Spring and other personal care brands Colgate is reportedly working with Goldman Sachs to sell some mass-market personal care brands, potentially raising over $1 billion. Selling slower-growing brands could sharpen focus on core oral care, but it also means giving up revenue. The net effect on the stock is unclear.
This is a major strategic move that could reshape the company and is the latest news in the period.

Latest31 Jul – 11 Sep 2026

▼2

Colgate beats on earnings but tariffs, weak volumes and index exit weigh

Q2 earnings beat, guidance raised, but tariff costs cloud outlook Colgate beat profit and sales estimates, with margins expanding and full-year earnings guidance raised. But management flagged rising tariff costs and raw materials, and the stock fell 1.8% on the day. The market is weighing solid results against cost pressures ahead.
This is the core earnings event that sets the tone for the period and explains the mixed price reaction.
U.S. volumes flat as shoppers switch to cheaper store brands Colgate's U.S. sales volumes were flat or falling as shoppers trade down to private-label and newer brands. This squeezes growth in its home market and pressures pricing power. It's a broad industry problem, but it directly limits how fast Colgate can grow.
This demand weakness is a key reason the stock struggles despite the earnings beat.
Removed from S&P 100 index, forcing some funds to sell Colgate is being dropped from the S&P 100 index, which means index-tracking funds must sell their shares. That creates mechanical selling pressure around the change date. It doesn't reflect the business itself, but it can push the price down in the short term.
This is a concrete, new event that adds selling pressure on the stock.
Exploring sale of Softsoap, Irish Spring and other personal care brands Colgate is reportedly working with Goldman Sachs to sell some mass-market personal care brands, potentially raising over $1 billion. Selling slower-growing brands could sharpen focus on core oral care, but it also means giving up revenue. The net effect on the stock is unclear.
This is a major strategic move that could reshape the company and is the latest news in the period.

Kimberly-Clark Corporation (KMB)

Q3 202617 Jun – 8 Sep 2026

▲2▼2

Kimberly-Clark's Kenvue bet meets China and cost setbacks

Kenvue acquisition adds major brands Kimberly-Clark agreed to buy Kenvue for $48.7 billion, adding Tylenol and Listerine. The deal is expected to create cost savings and more sales, expanding the company's consumer health business.
This is the biggest new event of the quarter and a key positive driver.
Defensive appeal and dividend strength Kimberly-Clark's everyday products, 4.7% dividend yield, and 54-year record of raising dividends attract income investors. The stock also trades below its usual valuation, offering a margin of safety.
This explains why investors might still favor the stock despite risks.
Regulatory and integration risks for Kenvue deal The Kenvue deal faces reviews in China and the EU that could delay or change it. Integrating Kenvue also brings execution challenges, and Kenvue itself struggles with inflation and tariffs pressuring its profit margins.
These are major new risks that could hurt the deal's success and KMB's stock.
Outlook cut on China allegations and cost pressures Kimberly-Clark lowered its 2026 outlook after China diaper-quality claims and weaker revenue. A distribution-center fire, Middle East conflict, and higher oil prices are adding costs, weighing on results.
This directly explains the negative revision and operational headwinds this quarter.

August 202629 Jul – 8 Sep 2026

▼1

Kenvue deal advances but regulatory and earnings risks weigh on KMB

Q2 earnings beat but 2026 outlook cut on China allegations Kimberly-Clark beat profit expectations but missed revenue and lowered its full-year outlook, citing profit pressure from false diaper quality allegations in China. The stock trades below analyst targets, and the lowered guidance signals weaker near-term earnings, which pushes the price down.
This is the core earnings event of the period and directly explains why KMB is under pressure.
China antitrust review deepens, adding delay risk to Kenvue deal China's market regulator moved the $49 billion Kenvue acquisition into a phase 2 review, which could delay or change the deal. Even though shares rose slightly that day, a longer review creates uncertainty about whether the deal closes on time and on the expected terms.
This is a new regulatory hurdle that could affect the deal's timing and value, a key driver for KMB.
EU approval sought for Kenvue deal, another regulatory step Kimberly-Clark asked the European Union for permission to buy Kenvue, moving the deal into another review stage. The EU filing is a request, not an approval, so the outcome and any conditions remain uncertain, keeping a cloud over the deal's completion.
This is a new regulatory development that adds to the deal's uncertainty and is not yet in earlier reports.
Kenvue deal nears close but integration and financial risks remain The Kenvue combination has cleared shareholder and U.S. antitrust hurdles and is expected to close in Q4 2026, but Kenvue's recent results showed margin pressure from inflation and tariffs, and the deal still faces foreign approvals and execution risk. The benefits may not be fully realized, which could limit upside for KMB.
This summarizes the latest status and risks of the deal, a major factor for KMB's future earnings and stock price.

Latest29 Jul – 8 Sep 2026

▼1

Kenvue deal advances but regulatory and earnings risks weigh on KMB

Q2 earnings beat but 2026 outlook cut on China allegations Kimberly-Clark beat profit expectations but missed revenue and lowered its full-year outlook, citing profit pressure from false diaper quality allegations in China. The stock trades below analyst targets, and the lowered guidance signals weaker near-term earnings, which pushes the price down.
This is the core earnings event of the period and directly explains why KMB is under pressure.
China antitrust review deepens, adding delay risk to Kenvue deal China's market regulator moved the $49 billion Kenvue acquisition into a phase 2 review, which could delay or change the deal. Even though shares rose slightly that day, a longer review creates uncertainty about whether the deal closes on time and on the expected terms.
This is a new regulatory hurdle that could affect the deal's timing and value, a key driver for KMB.
EU approval sought for Kenvue deal, another regulatory step Kimberly-Clark asked the European Union for permission to buy Kenvue, moving the deal into another review stage. The EU filing is a request, not an approval, so the outcome and any conditions remain uncertain, keeping a cloud over the deal's completion.
This is a new regulatory development that adds to the deal's uncertainty and is not yet in earlier reports.
Kenvue deal nears close but integration and financial risks remain The Kenvue combination has cleared shareholder and U.S. antitrust hurdles and is expected to close in Q4 2026, but Kenvue's recent results showed margin pressure from inflation and tariffs, and the deal still faces foreign approvals and execution risk. The benefits may not be fully realized, which could limit upside for KMB.
This summarizes the latest status and risks of the deal, a major factor for KMB's future earnings and stock price.

July 202617 Jun – 24 Jul 2026

▲3▼1

Kimberly-Clark's $48.7B Kenvue Deal and Defensive Strength Drive Upside

Kenvue acquisition to create high-margin powerhouse Kimberly-Clark is acquiring Kenvue for $48.7 billion, adding brands like Tylenol and Listerine. The deal is expected to deliver $1.9–2.1 billion in cost synergies and $500 million in profit from revenue synergies within a few years. This expands KMB's portfolio and boosts long-term earnings power.
The Kenvue deal is the biggest strategic move and directly affects KMB's future growth and profitability.
Defensive business and dividend appeal Kimberly-Clark's recession-resistant brands like Huggies and Kleenex provide steady demand. The stock offers a 4.7% dividend yield and has raised dividends for 54 straight years. It trades at about 14 times earnings, below its historical average, making it attractive to income and value investors.
This explains why investors are willing to pay up for KMB despite market volatility.
Arbex joint venture sharpens focus on higher-margin products Kimberly-Clark formed a joint venture called Arbex with Suzano, offloading its lower-margin paper-towel and tissue business. This frees up resources to integrate Kenvue and focus on higher-margin personal-care products, potentially improving overall profitability.
This strategic move supports margin expansion and the Kenvue integration.
Integration and cost risks could weigh on results The Kenvue deal brings execution and integration risks. Also, a California distribution center fire and Middle East conflict inflation are expected to cut second-quarter revenue by $20 million and earnings by $50 million. If oil averages $100 per barrel, additional input costs of $150–170 million could hit the second half.
These are real near-term headwinds that could pressure KMB's stock if they worsen.

17 Jun – 24 Jul 2026

▲3▼1

Kimberly-Clark's $48.7B Kenvue Deal and Defensive Strength Drive Upside

Kenvue acquisition to create high-margin powerhouse Kimberly-Clark is acquiring Kenvue for $48.7 billion, adding brands like Tylenol and Listerine. The deal is expected to deliver $1.9–2.1 billion in cost synergies and $500 million in profit from revenue synergies within a few years. This expands KMB's portfolio and boosts long-term earnings power.
The Kenvue deal is the biggest strategic move and directly affects KMB's future growth and profitability.
Defensive business and dividend appeal Kimberly-Clark's recession-resistant brands like Huggies and Kleenex provide steady demand. The stock offers a 4.7% dividend yield and has raised dividends for 54 straight years. It trades at about 14 times earnings, below its historical average, making it attractive to income and value investors.
This explains why investors are willing to pay up for KMB despite market volatility.
Arbex joint venture sharpens focus on higher-margin products Kimberly-Clark formed a joint venture called Arbex with Suzano, offloading its lower-margin paper-towel and tissue business. This frees up resources to integrate Kenvue and focus on higher-margin personal-care products, potentially improving overall profitability.
This strategic move supports margin expansion and the Kenvue integration.
Integration and cost risks could weigh on results The Kenvue deal brings execution and integration risks. Also, a California distribution center fire and Middle East conflict inflation are expected to cut second-quarter revenue by $20 million and earnings by $50 million. If oil averages $100 per barrel, additional input costs of $150–170 million could hit the second half.
These are real near-term headwinds that could pressure KMB's stock if they worsen.